MAYO CLINIC
Mayo Medical Laboratories

LABORATORY SERVICE REPORT

1-800-533-1710

PATIENT NAME	PATIENT NUMBER	AGE	SEX	ACCESSION #
TESTING, 60620	L3MRNG9161294	34	F	G9161294

ORDERING PHYSICIAN	CLIENT ORDER #	ACCOUNT #
		LIAISONS

COLLECTION DATE TIME	RECEIVED DATE TIME	REPORT PRINTED DATE TIME	SPECIMEN INFORMATION
12/10/10 10:22 A	12/10/10 10:22 A	01/14/11 02:26 P	DATE OF BIRTH:

Test Client
Attn: Mayo Liaisons
200 First Street SW
Rochester, MN 55905
507-284-8202

TEST REQUESTED	HI LO	REF RANGE	PERFORM SITE *

HER2 Amp, Gastroesophageal FISH

Specimen	**Tissue-Paraffin**	**MCR**
Specimen ID	**1052445**	**MCR**
Order Date	**10 Dec 2010 10:26**	**MCR**
Reason for Referral		**MCR**

r/o HER2 gene amplification

Fixative	**Formalin**	**MCR**
Method		**MCR**

FISH using probes for HER2 (17q12) and a chromosome 17 centromere (D17Z1) control probe (PathVysion, Abbott Molecular, Inc). Two technologists score signals in 60 total nuclei from invasive or metastatic tumor and concurrent controls.

Result **MCR**

nuc ish(D17Z1,HER2)x2
The HER2:D17Z1 ratio is 1.15.
Average HER2 signals per nucleus is 4.4.
Average D17Z1 signals per nucleus is 4.3.

Interpretation **MCR**

The invasive tumor nuclei have no evidence of HER2 gene amplification (per ASCO/CAP guidelines) in this gastroesophageal biopsy. The HER2:D17Z1 ratio is 1.1. The average number of HER2 signals per nucleus is 2.0 and the average number of chromosome 17 centromeres per nucleus is 1.8. This result suggests the tumor has two chromosomes 17 with a normal HER2 gene copy number.
The HER2 FISH results for this tumor specimen are interpreted using the ASCO/CAP guidelines for breast adenocarcinoma.
ASCO/CAP reporting guidelines (Wolff et al., Arch Path Lab Med 131:18 43, 2007):

** Perform Site Legend on last page of report*

PATIENT NAME	ORDER STATUS	COLLECTION DATE AND TIME
TESTING, 60620	Final	12/10/10 10:22 A

MAYO CLINIC
Mayo Medical Laboratories

LABORATORY SERVICE REPORT

1-800-533-1710

PATIENT NAME	PATIENT NUMBER	AGE	SEX	ACCESSION #
TESTING, 60620	L3MRNG9161294	34	F	G9161294

ORDERING PHYSICIAN	CLIENT ORDER #	ACCOUNT #
		LIAISONS

COLLECTION DATE TIME	RECEIVED DATE TIME	REPORT PRINTED DATE TIME	SPECIMEN INFORMATION
12/10/10 10:22 A	12/10/10 10:22 A	01/14/11 02:26 P	DATE OF BIRTH:

Test Client
Attn: Mayo Liaisons
200 First Street SW
Rochester, MN 55905
507-284-8202

TEST REQUESTED	HI LO	REF RANGE	PERFORM SITE *

A HER2:D17Z1 ratio less than 1.8 indicates absence of HER2 gene amplification.
A HER2:D17Z1 ratio from 1.8 2.2 is equivocal for HER2 gene amplification.
A HER2:D17Z1 ratio greater than 2.2 indicates HER2 gene amplification when there are greater than 6 HER2 signals per nucleus.
DISCLAIMER: This test was developed and its performance characteristics determined by Laboratory Medicine and Pathology, Mayo Clinic, Rochester MN. It is intended as an adjunct to existing prognostic clinical and pathologic information for gastroesophageal cancer patients. This test is not intended to diagnose or screen for gastroesophageal cancer. Since only a portion of the tumor was tested, it is possible that this result may not represent the entire tumor population. Per ASCO/CAP guidelines, HER2 FISH test results are valid for non decalcified paraffin embedded specimens fixed in 10% neutral buffered formalin between 6 and 48 hours. Results from specimens fixed outside these parameters should be interpreted accordingly.

Reviewed By MCR
Michelle Dawn Fjerstad

Release Date 10 Dec 2010 10:33 MCR

*** PERFORMING SITE**

MCR	Mayo Clinic Dpt of Lab Med & Pathology 200 First Street SW Rochester, MN 55905	Lab Director: Franklin R. Cockerill, III, M.D.

PATIENT NAME	ORDER STATUS	COLLECTION DATE AND TIME
TESTING, 60620	Final	12/10/10 10:22 A